Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chromosomal aberrations

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Chromosomal aberrations. Displaying page 1 of 1.
    EudraCT Number: 2015-001476-22 Sponsor Protocol Number: 04-30 Start Date*: 2016-02-16
    Sponsor Name:Onconova Therapeutics, Inc.
    Full Title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
    Medical condition: Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HR (Completed) PL (Prematurely Ended) SE (Completed) BE (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004444-19 Sponsor Protocol Number: CRIT124D2201 Start Date*: 2016-04-05
    Sponsor Name:Novartis Pharmaceutical corporation
    Full Title: An open-label, behavioral-treatment-controlled evaluation of the effects of extended release methylphenidate (Ritalin® LA) on the frequency of cytogenetic abnormalities in children 6 - 12 years of ...
    Medical condition: To determine whether the administration of extended-release methylphenidate in treatment-naïve children with ADHD affects the frequency of chromosomal abnormalities.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006380-22 Sponsor Protocol Number: ERMM1-200601 Start Date*: 2007-02-22
    Sponsor Name:CIS bio international
    Full Title: Biological dosimetry in radiation synovectomy of small finger joints with Erbium [169Er] citrate
    Medical condition: Patients with rheumatoid arthritis or seronegative spondylarthropathy with at least one inflamed finger joint (MCP, PIP, DIP) referred for RSO with with Erbium [169Er]citrate
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011208-42 Sponsor Protocol Number: HTA0830801 Start Date*: 2010-02-18
    Sponsor Name:Imperial College, London [...]
    1. Imperial College, London
    2. Academic Medical Center Amsterdam
    Full Title: First trimester progesterone therapy to reduce miscarriages in women with a history of unexplained recurrent miscarriages: A randomised, double blind, placebo-controlled, multi-centre trial [The PR...
    Medical condition: Recurrent Miscarriage
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016489-10 Sponsor Protocol Number: TPF-C-HIT Start Date*: 2010-08-23
    Sponsor Name:University of Heidelberg
    Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc...
    Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004360-26 Sponsor Protocol Number: CLL16 Start Date*: 2021-08-24
    Sponsor Name:German CLL Study Group (University of Cologne)
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002830-36 Sponsor Protocol Number: EORTC 06011 Start Date*: 2005-11-09
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10 % blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocy...
    Medical condition: The myelodysplastic syndrome (MDS) comprises a heterogenous group of hematopoietic stem cell disorders. - quantitative and morphologic abnormalities of bone marrow and peripheral blood cells - c...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10028536 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001691-41 Sponsor Protocol Number: EMN29 Start Date*: 2021-12-28
    Sponsor Name:European Myeloma Network
    Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002792-42 Sponsor Protocol Number: RV-FOL-GELARC-0683 Start Date*: 2012-07-17
    Sponsor Name:LYSARC
    Full Title: A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide ( CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previous...
    Medical condition: stage II-IV follicular lymphoma grade 1-3a not previously treated
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016908 Follicle centre lymphoma, follicular grade I, II, III stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016910 Follicle centre lymphoma, follicular grade I, II, III stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016909 Follicle centre lymphoma, follicular grade I, II, III stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed) PT (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:08:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA